Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Last trade$0.8202
Day change-$0.055 (-6.28%)
Day range$0.82 – $0.925
Volume196,503
Market cap$14M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$14.08M
Price / earnings
—
Price / book
3.98×
Price / sales
40.8×
EV / sales
56.18×
EV / EBITDA
-1.79×
Profitability
Earnings per share
-$0.77
Return on assets
-38.41%
Return on equity
-348.81%
Dividend yield
0%
Liquidity and leverage
Debt / equity
6.3×
Current ratio
1.11×
Quick ratio
1.11×
Cash ratio
0.59×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.78M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALLR, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$25K
$320K
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$25K
$320K
$0
$0
$0
$0
$0
Selling, general and administrative
$1.33M
$1.42M
$1.56M
$1.32M
$1.81M
$1.63M
$5.47M
$1.59M
Research and development
$1.35M
$1.3M
$1.67M
$1.2M
$2.32M
$1.4M
$1.85M
$1.02M
Total operating expenses
$2.67M
$2.71M
$3.24M
$2.52M
$4.13M
$3.04M
$7.32M
$12.31M
Operating income
-$2.67M
-$2.69M
-$2.92M
-$2.52M
-$4.13M
-$3.04M
-$7.32M
-$12.31M
Interest expense
-$719K
-$229K
-$59K
-$57K
-$12K
-$57K
-$75K
-$50K
Income before taxes
-$3.41M
-$2.75M
-$3.37M
-$2.81M
-$2.32M
-$2.73M
-$7.45M
-$11.97M
Income taxes
$0
$0
$0
$0
$0
$0
$0
-$377K
Net income
-$3.41M
-$2.75M
-$3.37M
-$2.81M
-$2.32M
-$2.73M
-$7.45M
-$11.59M
Net income attributable to common shareholders
-$3.41M
-$2.75M
-$3.37M
-$2.81M
-$2.32M
-$2.73M
-$7.45M
-$12.15M
EBITDA
-$2.64M
-$2.71M
-$2.91M
-$2.56M
-$4.12M
-$3.03M
-$7.32M
-$2.61M
Basic earnings per share
-$0.21
-$0.17
-$0.21
-$0.19
-$0.15
-$0.25
-$1.71
-$7.71
Diluted earnings per share
-$0.21
-$0.17
-$0.21
-$0.19
-$0.15
-$0.25
-$1.71
-$7.71
Recent news
Company coverage with links to the original publishers.
Allarity Therapeutics (ALLR) has formed a hammer chart pattern, suggesting potential trend reversal after recent declines. The stock is supported by strong analyst agreement on raising earnings estimates, with consensus EPS estimates up 13% over the last 30 days. ALLR holds a Zacks Rank #2 (Buy), placing it in the top 20% of rated stocks.
Allarity Therapeutics expanded its in-house medical laboratory to include proteomics and cell line research capabilities, building on existing transcriptomics and CLIA clinical testing services. The expansion aims to deepen mechanism-of-action research for stenoparib, its dual PARP and WNT pathway inhibitor, while broadening external research services. The company expects cost efficiencies without impacting current cash runway.
Allarity Therapeutics announced it will present a Trial-in-Progress poster on its Phase 2 stenoparib trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen. The poster will outline the study design and clinical rationale for evaluating stenoparib, a dual PARP and WNT pathway inhibitor, in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. The presentation will be led by Principal Investigator Dr. Kathleen N. Moore, a leading expert in gynecologic oncology.
Over 25 pharmaceutical companies are actively developing 30+ PARP inhibitor drugs in clinical trials, with major players including AstraZeneca, Gilead Sciences, and Nerviano Medical Sciences advancing promising candidates like Saruparib and NMS-293. The pipeline shows robust activity across multiple cancer indications including breast cancer, prostate cancer, and glioblastoma, with approximately 12+ drugs in early to mid-stage development. Recent developments include clinical collaborations and first-in-human trial updates from companies like Acerand Therapeutics and Synnovation Therapeutics.
Allarity Therapeutics announced that the US Patent and Trademark Office has issued a Notice of Allowance for its stenoparib DRP® companion diagnostic patent application. The patent, expected to be formally granted within three months, would provide exclusivity for stenoparib when used with the DRP test at least through 2039. The allowed claims cover methods for predicting clinical benefit and selecting patients most likely to benefit from stenoparib treatment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.